Sharekhan

Indegene Ltd

Thu 13/03/2025,15:53:33 | NSE : INDGN

₹ 513.30-9.25 (-1.77%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 526.80

Previous Close

₹ 522.55

Volume

819134

Mkt Cap ( Rs. Cr)

₹12281.67

High

₹ 538.00

Low

₹ 507.95

52 Week High

₹ 736.30

52 Week Low

₹ 470.10

Book Value Per Share

₹ 98.64

Dividend Yield

0.00

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Indegene Ltd

Your Vote -

Buy

75.00%

Hold

0.00%

Sell

25.00%

75.00%

4 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

513.30

61

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

61

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Indegene Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Indegene - Alteration Of Capital and Fund Raising-XBRL

    14 Mar 2025, 5:03PM INDEGENE LIMITED has informed the Exchange regarding Allotment of Securities
  • Indegene - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    14 Mar 2025, 5:01PM INDEGENE LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
  • Indegene - General Updates

    13 Mar 2025, 8:02PM Indegene Limited has informed the Exchange about outcome of circular resolution regarding reappointment of Independent Directors subject to shareholde
  • Indegene - Intimation Of Outcome Of Resolution Passed By Circulation

    13 Mar 2025, 7:57PM Reappointment of Independent Directors subject to shareholder approval and allotment of shares under the RSU plan 2020
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    10 Mar 2025, 5:20PM Indegene Limited has informed the Exchange about Intimation for hosting `Investor Day .
  • Indegene - Press Release

    10 Mar 2025, 10:59AM Indegene Limited has informed the Exchange regarding a press release dated March 10, 2025, titled ""Press Release - Deloitte Names Indegene a Winner o
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    10 Mar 2025, 5:28PM Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform the Stock Exchanges that the
  • Deloitte names Indegene a Winner of Enterprise Growth Awards 2025

    10 Mar 2025, 12:03PM Indegene, a digital-first life sciences commercialization company, has been honored as one of the standout winners of Deloitte Private’s Enterpr
  • Indegene - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    10 Mar 2025, 10:58AM Pursuant to Regulation 30 of SEBI(LODR) Regulations, 2015, enclosed herewith is a press release dated March 10, 2025, titled \r\n'Deloitte Names Indeg
  • Indegene - Updates

    6 Mar 2025, 7:37PM Indegene Limited has informed the Exchange regarding 'Change in website address of investor relation page.'.
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    6 Mar 2025, 5:10PM Indegene Limited has informed the Exchange about Schedule of meet of Analyst / Investor(s) Meeting(s).
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    6 Mar 2025, 5:15PM Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015, we would like to inform you that the Officials o
  • Indegene - Alteration Of Capital and Fund Raising-XBRL

    24 Feb 2025, 3:51PM INDEGENE LIMITED has informed the Exchange regarding Allotment of Securities
  • Indegene - Updates

    24 Feb 2025, 11:32AM Indegene Limited has informed the Exchange regarding 'Intimation of outcome of resolution passed by Circulation under Regulation 30 of the SEBI (Listi
  • Indegene - Press Release

    24 Feb 2025, 10:50AM Indegene Limited has informed the Exchange regarding a press release dated February 24, 2025, titled "" Indegene Launches Cortex, A Fit-For-Purpose Ge
  • Indegene - Intimation Of Outcome Of Resolution Passed By Circulation Under Regulation 30 Of The SEBI (Listing Obligations And

    24 Feb 2025, 11:40AM Allotment of shares under RSU Plan 2020 and ESOP Plan 2020
  • Indegene - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    24 Feb 2025, 10:51AM Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, enclosed herewith is a press release dated February 24, 2025, titled 'Indegene Launches
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    20 Feb 2025, 3:52PM Indegene Limited has informed the Exchange about Schedule of meet
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    20 Feb 2025, 3:47PM Indegene Limited has informed the Exchange about Schedule of meet.
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    20 Feb 2025, 3:54PM Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    20 Feb 2025, 3:50PM Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the
  • Indegene - General Updates

    18 Feb 2025, 3:45PM Indegene Limited has informed the Exchange about resolution proposed to be passed by Circulation under Regulation 30 of the SEBI (Listing Obligations
  • Indegene - Intimation Of Resolution Proposed To Be Passed By Circulation.

    18 Feb 2025, 3:46PM Pursuant to Regulation 30 of the SEBILODR Regulations, 2015, we hereby inform you that the following resolutions of Board of Directors of Indegene Lim
  • Indegene - Intimation Regarding The Change Of Name Of Registrar And Transfer Agent ('RTA') From 'Link Intime India Private Li

    13 Feb 2025, 8:09PM This is to inform you that the company has received an email communication from its RTA on February 13, 2025, the RTA name has been changed from \LINK
  • Indegene - Updates

    13 Feb 2025, 8:01PM Indegene Limited has informed the Exchange regarding 'Intimation regarding the change of name of Registrar and Transfer Agent ( RTA ) from Link Intim
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    13 Feb 2025, 7:35PM Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    13 Feb 2025, 7:31PM \r\nPursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    13 Feb 2025, 7:30PM Indegene Limited has informed the Exchange about Schedule of meet
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    13 Feb 2025, 7:28PM Indegene Limited has informed the Exchange about Schedule of meet
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    13 Feb 2025, 7:27PM Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    13 Feb 2025, 7:25PM Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    13 Feb 2025, 7:25PM Indegene Limited has informed the Exchange about Schedule of meet
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    13 Feb 2025, 7:22PM Indegene Limited has informed the Exchange about Schedule of meet
  • Indegene - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    13 Feb 2025, 7:12PM Pursuant to Regulation 326 of SEBI LODR Regulations, 2015 read with Regulation 414 of SEBI ICDR Regulations, 2018, Please find attached Monitoring Age
  • Indegene - Monitoring Agency Report

    13 Feb 2025, 7:01PM Intimation of Monitoring Agency Report for the quarter ended December 31, 2024 .
  • Indegene - Integrated Filing (Financial)

    13 Feb 2025, 6:37PM Revised Integrated Filing Financial for the quarter ended 31st December 2024.
  • Indegene - Integrated Filing- Financial

    13 Feb 2025, 6:09PM Integrated Filing (Financial) for the quarter ended on December 31, 2024 .
  • Indegene - Statement of deviation(s) or variation(s) under Reg. 32

    13 Feb 2025, 5:17PM Indegene Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
  • Indegene - Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds For The Quarter Ended December 31, 2024

    13 Feb 2025, 5:25PM Pursuant to Reg 32 of SEBILODR Regulations, 2015, we hereby attach statement of Deviation/Variation in utilization of funds raised through Public Issu
  • Indegene - Press Release

    11 Feb 2025, 5:29PM Indegene Limited has informed the Exchange regarding a press release dated February 11, 2025, titled "" Everest Group Recognizes Indegene as a Front-R
  • Indegene - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    11 Feb 2025, 5:35PM Pursuant to Reg 30 of SEBILODR Regulations, 2015, enclosed herewith is a press release dated February 11, 2015, titled 'Everest Group Recognizes Indeg
  • Indegene - Integrated Filing- Financial

    10 Feb 2025, 5:37PM Integrated Filings - Financial Q3FY25
  • Indegene - Integrated Filing (Financial)

    10 Feb 2025, 5:58PM Integrated Filing (financial) for the quarter ended 31st December 2024
  • Indegene - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    6 Feb 2025, 3:20PM Pursuant to Regulation 30 of the SEBILODR, Regulation, 2015, please find enclosed the transcript of the conference call for the quarter ended December
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    6 Feb 2025, 3:20PM Indegene Limited has informed the Exchange about Transcript of the conference call.
  • Indegene - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    6 Feb 2025, 12:04PM Pursuant to Reg 30 of SEBILODR Regulation, 2015, enclosed herewith is a press release dated FEB 06, 2025, titled 'Indegene Expands Footprint in Europe
  • Indegene - Press Release

    6 Feb 2025, 12:01PM Indegene Limited has informed the Exchange regarding a press release dated February 06, 2025, titled "" Indegene Expands Footprint in Europe, Launches
  • Indegene - Alteration Of Capital and Fund Raising-XBRL

    31 Jan 2025, 5:28PM INDEGENE LIMITED has informed the Exchange regarding Allotment of Securities
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    31 Jan 2025, 4:37PM Pursuant to Regulation 30 and 46(2)(o) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, \r\nthe audio recording of the
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    31 Jan 2025, 4:21PM Indegene Limited has informed the Exchange about Link of Recording
  • Indegene - Trading Window

    31 Jan 2025, 4:05PM Indegene Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
  • Indegene - Copy of Newspaper Publication

    31 Jan 2025, 3:54PM Indegene Limited has informed the Exchange about Copy of Newspaper Publication
  • Indegene - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    31 Jan 2025, 11:14AM INDEGENE LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
  • Indegene - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s

    30 Jan 2025, 7:23PM Pursuant to Regulation 30 of SEBILODR Regulation, 2015, we hereby inform you that the Board of Directors of Indegene Limited at its meeting held today
  • Indegene - Alteration Of Capital and Fund Raising-XBRL

    30 Jan 2025, 7:20PM INDEGENE LIMITED has informed the Exchange regarding Allotment of Securities
  • Indegene - Change in Auditors

    30 Jan 2025, 7:15PM Indegene Limited has informed the Exchange regarding Change in Auditors of the company.
  • Indegene - Announcement under Regulation 30 (LODR)-Investor Presentation

    30 Jan 2025, 6:06PM Pursuant to Regulation 30 of the SEBI LODR Regulation, 2015, the Analyst presentation and fact sheet for the Q3FY25 with respect to financial results
  • Indegene Q3 net profit jumps 65.78% at Rs 49.90 cr

    30 Jan 2025, 6:00PM The company reported standalone net profit of Rs 49.90 crore for the quarter ended December 31, 2024 as compared to Rs 30.10 crore in the same period
  • Indegene - Investor Presentation

    30 Jan 2025, 5:56PM Indegene Limited has informed the Exchange about Investor Presentation
  • Indegene - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    30 Jan 2025, 5:56PM We wish to inform you that the company has made a press release dated January 30, 2025, announcing the financial results for the quarter ended Decembe
  • Indegene - Press Release

    30 Jan 2025, 5:50PM Indegene Limited has informed the Exchange regarding a press release dated January 30, 2025, titled ""Press Release regarding financial results for th
  • Indegene - Financial Result Updates

    30 Jan 2025, 5:13PM Indegene Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
  • Indegene - Outcome of Board Meeting

    30 Jan 2025, 5:11PM Indegene Limited has informed the Exchange regarding Board meeting held on January 30, 2025.
  • Indegene - Board Meeting Outcome for Intimation Of Outcome Of Board Meeting

    30 Jan 2025, 5:11PM Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Dire
  • Indegene - Results, Financial Results- Dec 2024

    30 Jan 2025, 5:38PM The unaudited consolidated financial results of the company and its subsidiaries as per INDAS for the quarter ended December 31, 2024 along with the L
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    24 Jan 2025, 10:31PM Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:\r\n\r\nIndegene Q3FY25 Earnings Call\r\nFri
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    24 Jan 2025, 10:24PM Indegene Limited has informed the Exchange about Schedule of meet
  • Indegene - Board Meeting Intimation

    24 Jan 2025, 10:19PM INDEGENE LIMITED has informed the Exchange about Board Meeting to be held on 30-Jan-2025 to consider and approve the Quarterly Unaudited Financial res
  • Indegene - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And

    24 Jan 2025, 10:17PM Indegene Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2025 ,inter alia, to consider and approve
  • Indegene - Options to purchase securities

    23 Jan 2025, 12:04AM Indegene Limited has informed the exchange about intimation of grant .
  • Indegene - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    23 Jan 2025, 12:07AM Intimation of grant under company stock option schemes.
  • Indegene has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024

    20 Jan 2025, 8:30PM As of December 2024, 100.00% owned by Public. <p align=justify> Institutional holds 9.02% (Insurance Companies 0.10%) and Non-Institutional holds 91.0
  • Indegene - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    20 Jan 2025, 1:27PM Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2024
  • Indegene - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    20 Jan 2025, 1:22PM Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2024.
  • Indegene - Press Release

    17 Jan 2025, 11:04AM Indegene Limited has informed the Exchange regarding a press release dated January 17, 2025, titled ""Indegene Wins BIG Innovation Award_January 2025.
  • Indegene - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    17 Jan 2025, 11:03AM Indegene wins Big Innovation Award January 2025
  • Indegene - Press Release

    9 Jan 2025, 4:50PM Indegene Limited has informed the Exchange regarding a press release dated January 09, 2025, titled ""CliniOps Announces Strategic Partnership with In
  • Indegene - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    9 Jan 2025, 4:43PM Pursuant to Regulation 30 of the SEBI LODR Regulation, 2015, enclosed herewith is a press release dated January 09,2025, titled 'CliniOps Announces st
  • Indegene - Trading Window-XBRL

    30 Dec 2024, 6:14PM Indegene Limited has informed the Exchange about Closure of Trading Window
  • Indegene - Trading Window

    30 Dec 2024, 6:06PM Indegene Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
  • Indegene - General Updates

    27 Dec 2024, 10:07PM Indegene Limited has informed the Exchange about intimation of resolution passed by circular
  • Indegene - Updates

    27 Dec 2024, 9:54PM Indegene Limited has informed the Exchange regarding 'Intimation under Reg 7(2)'.
  • Indegene - Updates

    23 Dec 2024, 11:12PM Indegene Limited has informed the Exchange regarding 'Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulation, 2015''.
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    18 Dec 2024, 8:07PM Intimation of Schedule of Investor / Analyst meeting under the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    18 Dec 2024, 8:01PM Indegene Limited has informed the Exchange about Schedule of meet
  • Indegene - Intimation Of Resolution Proposed To Be Passed By Circulation

    18 Dec 2024, 7:52PM Intimation of Resolution proposed to be passed by Circulation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regula
  • Indegene - General Updates

    18 Dec 2024, 7:49PM Indegene Limited has informed the Exchange about Intimation of Resolution proposed to be passed by Circulation
  • Indegene - Updates

    18 Dec 2024, 7:37PM Indegene Limited has informed the Exchange regarding 'Disclosure as per Regulation 7(2) of SEBI (PIT) Regulation 2015'.
  • Indegene - Disclosure As Per Regulation 7(2) Of SEBI (PIT) Regulation, 2015

    18 Dec 2024, 7:34PM Disclosure under Regulation 7(2) of the SEBI (PIT) Regulation, 2015
  • Indegene - Press Release

    17 Dec 2024, 10:29AM Indegene Limited has informed the Exchange regarding a press release dated December 17, 2024, titled ""Indegene Recognized Among Top 50 Companies with
  • Indegene - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    17 Dec 2024, 10:34AM Indegene recognized among Top 50 Companies with Great Managers in the Great Manager Awards 2024 by People Business
  • Indegene

    3 Dec 2024 , 11:16AM Global private equity firm Carlyle-backed CA Dawn Investments likely to divest 2.9% stake in Indegene via block deal at Rs.615 per share. As per media sources, the sale could raise approximately Rs 470 crore, based on the offered floor price.
  • Indegene announces strategic collaboration with Microsoft

    11 Jul 2024 , 11:38AM Indegene collaborates with Microsoft to help life sciences companies scale up Generative AI adoption

Key fundamentals

Evaluate the intrinsic value of Indegene Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 953.8 795.3 650 442.2 333.6
Liabilities 953.8 795.3 650 442.2 333.6
Equity 44.4 44.3 0.4 0.3 0.3
Gross Profit 168 177.9 168.7 150.4 85.9
Net Profit 137.9 130.2 132.7 133.4 31.7
Cash From Operating Activities 176.2 81.9 38.2 54.6 89.6
NPM(%) 13.18 12.94 15.85 26.1 9.47
Revenue 1045.6 1005.7 836.7 511 334.5
Expenses 877.6 827.8 668 360.6 248.6
ROE(%) 5.84 5.51 5.62 5.65 1.34

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Indegene Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Visagar Polytex Ltd 0.82 -3.53 0.00 15050.69 -53.07 0.00
India Motor Parts and Accessories Ltd 915.95 -0.82 14.57 641.72 592.31 2.95
Madhya Pradesh Today Media Ltd 29.10 0.00 4.99 234.89 55.30 0.00
Hathway Cable and Datacom Ltd 13.20 -1.35 25.38 91018.54 28.05 0.00

Company Info

Our Company was incorporated as `Indegene Lifesystems Private Limited' at Ahmedabad, Gujarat, as a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 16, 1998, issued by the Registrar of Companies, Gujarat, Dadra & Nagar Haveli at Ahmedabad. Thereafter, the registered office of our Company was shifted from Gujarat to Karnataka in June 2003, and then, from Karnataka to Maharashtra in May 2014. Further, pursuant to a resolution passed by our Shareholders at the EGM held on February 29, 2016, the name of our Company was changed to `Indegene Private Limited' and a fresh certificate of incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. The name of our Company was changed to better reflect the nature of business undertaken by our Company. Thereafter, the registered office of our Company was shifted from Maharashtra to Karnataka in February 2017. Subsequently, our Company was converted from a private limited company to a public limited company, pursuant to a special resolution passed by our Shareholders at the EGM held on November 7, 2022 and the name of our Company was changed to `Indegene Limited' and a fresh certificate of incorporation was issued to our Company by the RoC, on November 17, 2022.Major events and milestones:2005-Raised funding from Nadathur Holdings & Investments Private Limited-Expanded operations to the USA by incorporating a subsidiary named Indegene, Inc.-Expanded operations to Southeast Asia by incorporating a subsidiary named Indegene Fareast Pte. Ltd. in Singapore2006-Acquisition of Medsn, Inc.1 a company in the USA which is engaged in medical education and marketing business, by one of our Material Subsidiaries, Indegene, Inc.2 through the merger of Medsn Merger Sub, Inc., an erstwhile wholly owned subsidiary of Indegene, Inc. with Medsn, Inc.2007-Expanded our services to include European territory2008-Received BS ISO/IEC 27001:2005 certification for information security management system32009-Received ISO 9001:2000 certification for quality management system42012-Expanded operations to China by incorporating a subsidiary named Indegene Lifesystems Consulting (Shanghai) Co., Ltd.2017-Acquisition of the Encima Group, Inc., a corporation which operates a digital service, marketing automation and analytics services business supporting clients in healthcare, life sciences and other industries by one of our Material Subsidiaries, ILSL Holdings, Inc.2020-Acquisition of DT Associates Research and Consulting Services Limited, a consulting services company in UK supporting clients in healthcare, life sciences and other industries by one of our Material Subsidiaries, ILSL Holdings, Inc.-Launched Indegene Digital Summit, a symposium on digital transformation and customer experience in life sciences2021-Expanded operations to Japan by incorporating a subsidiary named Indegene Japan, LLC-Raised equity funding from CA Dawn Investments and Brighton Park Capital-Received BS ISO/IEC 27701:2019 certification for privacy information management system52022-Acquisition of Medical Marketing Economics, LLC by one of our Material Subsidiaries, ILSL Holdings, Inc. and subsequent merger of Medical Marketing Economics, LLC with Indegene, Inc.-Expanded global operations with new offices in Mexico2023-Acquisition of Cult Health, a company engaged in the business of providing advertising services to parties in the healthcare sector, by one of our Material Subsidiaries, ILSL Holdings, Inc.-Expanded our presence in Europe with the acquisition of Indegene Healthcare Germany GmbH (formerly Sotus 852 GmbH) by our subsidiary, Indegene Ireland Limited-Launched Invisage, an AI-enabled hybrid omnichannel sales and marketing platform2024-Acquisition of Trilogy Writing & Consulting GmbH, a company engaged in providing high-end medical writing to customers that include market-leading pharmaceutical companies, along with three of its wholly owned subsidiaries, by one of our Subsidiaries, Indegene Ireland Limited.-Ranked 167 in The Next 500 India's Largest Emerging Companies by Fortune India

Our Company was incorporated as `Indegene Lifesystems Private Limited' at Ahmedabad, Gujarat, as a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 16, 1998, issued by the Registrar of Companies, Gujarat, Dadra & Nagar Haveli at Ahmedabad. Thereafter, the registered office of our Company was shifted from Gujarat to Karnataka in June 2003, and then, from Karnataka to Maharashtra in May 2014. Further, pursuant to a resolution passed by our Shareholders at the EGM held on February 29, 2016, the name of our Company was changed to `Indegene Private Limited' and a fresh certificate of incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. The name of our Company was changed to better reflect the nature of business undertaken by our Company. Thereafter, the registered office of our Company was shifted from Maharashtra to Karnataka in February 2017. Subsequently, our Company was converted from a private limited company to a public limited company, pursuant to a special resolution passed by our Shareholders at the EGM held on November 7, 2022 and the name of our Company was changed to `Indegene Limited' and a fresh certificate of incorporation was issued to our Company by the RoC, on November 17, 2022.Major events and milestones:2005-Raised funding from Nadathur Holdings & Investments Private Limited-Expanded operations to the USA by incorporating a subsidiary named Indegene, Inc.-Expanded operations to Southeast Asia by incorporating a subsidiary named Indegene Fareast Pte. Ltd. in Singapore2006-Acquisition of Medsn, Inc.1 a company in the USA which is engaged in medical education and marketing business, by one of our Material Subsidiaries, Indegene, Inc.2 through the merger of Medsn Merger Sub, Inc., an erstwhile wholly owned subsidiary of Indegene, Inc. with Medsn, Inc.2007-Expanded our services to include European territory2008-Received BS ISO/IEC 27001:2005 certification for information security management system32009-Received ISO 9001:2000 certification for quality management system42012-Expanded operations to China by incorporating a subsidiary named Indegene Lifesystems Consulting (Shanghai) Co., Ltd.2017-Acquisition of the Encima Group, Inc., a corporation which operates a digital service, marketing automation and analytics services business supporting clients in healthcare, life sciences and other industries by one of our Material Subsidiaries, ILSL Holdings, Inc.2020-Acquisition of DT Associates Research and Consulting Services Limited, a consulting services company in UK supporting clients in healthcare, life sciences and other industries by one of our Material Subsidiaries, ILSL Holdings, Inc.-Launched Indegene Digital Summit, a symposium on digital transformation and customer experience in life sciences2021-Expanded operations to Japan by incorporating a subsidiary named Indegene Japan, LLC-Raised equity funding from CA Dawn Investments and Brighton Park Capital-Received BS ISO/IEC 27701:2019 certification for privacy information management system52022-Acquisition of Medical Marketing Economics, LLC by one of our Material Subsidiaries, ILSL Holdings, Inc. and subsequent merger of Medical Marketing Economics, LLC with Indegene, Inc.-Expanded global operations with new offices in Mexico2023-Acquisition of Cult Health, a company engaged in the business of providing advertising services to parties in the healthcare sector, by one of our Material Subsidiaries, ILSL Holdings, Inc.-Expanded our presence in Europe with the acquisition of Indegene Healthcare Germany GmbH (formerly Sotus 852 GmbH) by our subsidiary, Indegene Ireland Limited-Launched Invisage, an AI-enabled hybrid omnichannel sales and marketing platform2024-Acquisition of Trilogy Writing & Consulting GmbH, a company engaged in providing high-end medical writing to customers that include market-leading pharmaceutical companies, along with three of its wholly owned subsidiaries, by one of our Subsidiaries, Indegene Ireland Limited.-Ranked 167 in The Next 500 India's Largest Emerging Companies by Fortune India

Read More

Parent Organisation

Indegene Ltd.

Founded

16/10/1998

Managing Director

Mr.Manish Gupta

NSE Symbol

INDGNEQ

FAQ

The current price of Indegene Ltd is ₹ 513.30.

The 52-week high for Indegene Ltd is ₹ 538.00 and the 52-week low is ₹ 507.95.

The market capitalization of Indegene Ltd is currently ₹ 12281.67. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Indegene Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Indegene Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Indegene Ltd shares.

The CEO of Indegene Ltd is Mr.Manish Gupta, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT